Advanced search
Publication Cover
Leukemia & Lymphoma Volume 56, 2015 - Issue 12
Submit an article Journal homepage
327
Views
16
CrossRef citations to date
0
Altmetric
Letters to the Editor

The Revised International Prognostic Scoring System (IPSS-R) is not predictive of survival in patients with secondary myelodysplastic syndromes

Aziz NazhaLeukemia Program, Department of Hematology and Medical Oncology, Cleveland, OH, USA
,
David P. SeastoneLeukemia Program, Department of Hematology and Medical Oncology, Cleveland, OH, USA
,
Michael KengLeukemia Program, Department of Hematology and Medical Oncology, Cleveland, OH, USA
,
Sean HobsonLeukemia Program, Department of Hematology and Medical Oncology, Cleveland, OH, USA
,
Matt KalaycioLeukemia Program, Department of Hematology and Medical Oncology, Cleveland, OH, USA
,
Jaroslaw P. MaciejewskiDepartment of Translational Hematology and Oncology Research, Cleveland Clinic, Taussig Cancer Institute, Cleveland, OH, USA
&
Mikkael A. SekeresLeukemia Program, Department of Hematology and Medical Oncology, Cleveland, OH, USACorrespondence[email protected]
 show all
Pages 3437-3439 | Received 08 Mar 2015, Accepted 10 Apr 2015, Published online: 19 Jun 2015

References

  • Sekeres MA, Cutler C. How we treat higher-risk myelodysplastic syndromes. Blood 2014;123:829–836.
  • Garcia-Manero G. Myelodysplastic syndromes: 2014 update on diagnosis, risk-stratification, and management. Am J Hematol 2014;89:97–108.
  • Garcia-Manero G, Shan J, Faderl S, et al. A prognostic score for patients with lower risk myelodysplastic syndrome. Leukemia 2008;22:538–543.
  • Bejar R. Prognostic models in myelodysplastic syndromes. Hematology Am Soc Hematol Educ Program 2013;2013:504–510.
  • Zeidan AM, Gore SD, Padron E, Komrokji R. Current state of prognostication and risk stratification in myelodysplastic syndromes. Curr Opin Hematol 2015;22:146–154.
  • Malcovati L, Germing U, Kuendgen A, et al. Time-dependent prognostic scoring system for predicting survival and leukemic evolution in myelodysplastic syndromes. J Clin Oncol 2007;25:3503–3510.
  • Kantarjian H, O’Brien S, Ravandi F, et al. Proposal for a new risk model in myelodysplastic syndrome that accounts for events not considered in the original International Prognostic Scoring System. Cancer 2008;113:1351–1361.
  • Greenberg PL, Tuechler H, Schanz J, et al. Revised international prognostic scoring system for myelodysplastic syndromes. Blood 2012;120:2454–2465.
  • Schanz J, Tuchler H, Sole F, et al. New comprehensive cytogenetic scoring system for primary myelodysplastic syndromes (MDS) and oligoblastic acute myeloid leukemia after MDS derived from an international database merge. J Clin Oncol 2012;30:820–829.
  • Mishra A, Corrales-Yepez M, Ali NA, et al. Validation of the revised International Prognostic Scoring System in treated patients with myelodysplastic syndromes. Am J Hematol 2013;88: 566–570.
  • Lamarque M, Raynaud S, Itzykson R, et al. The revised IPSS is a powerful tool to evaluate the outcome of MDS patients treated with azacitidine: the GFM experience. Blood 2012;120: 5084–5085.
  • Neukirchen J, Lauseker M, Blum S, et al. Validation of the revised international prognostic scoring system (IPSS-R) in patients with myelodysplastic syndrome: a multicenter study. Leuk Res 2014;38: 57–64.
  • Sekeres MA, Swern AS, Fenaux P, et al. Validation of the IPSS-R in lenalidomide-treated, lower-risk myelodysplastic syndrome patients with del(5q). Blood Cancer J 2014;4:e242.
  • Vardiman JW, Thiele J, Arber DA, et al. The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. Blood 2009;114:937–951.
  • Greenberg P, Cox C, LeBeau MM, et al.International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood 1997;89:2079–2088.
  • Ok CY, Hasserjian RP, Fox PS, et al. Application of the international prognostic scoring system-revised in therapy-related myelodysplastic syndromes and oligoblastic acute myeloid leukemia. Leukemia 2014;28:185–189.
  • Quintas-Cardama A, Daver N, Kim H, et al. A prognostic model of therapy-related myelodysplastic syndrome for predicting survival and transformation to acute myeloid leukemia. Clin Lymphoma Myeloma Leuk 2014;14:401–410.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.